MedTrace Logo

Compassionate Use of Stiripentol in Dravet Syndrome

NCT01835314 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2019-10-04

No results posted yet for this study

Summary

Compassionate use of Stiripentol in Dravet Syndrome. This is a treatment protocol, not a research study, therefore children will only be monitored on a clinical basis for seizure improvement predominantly by parent and caregiver report.

Conditions

Interventions

DRUG

Stiripentol

Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Kelly Knupp, MD · University of Colorado/Children's Hospital Colorado

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01835314 on ClinicalTrials.gov